Biotech Crash: BioXcel Files Chapter 11, Stock Plunges 45%

PUBLISHED Aug 28, 2026, 9:36 AM ET

BioXcel Therapeutics Inc. announced on August 28, 2026, that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the United States to facilitate a structured asset sale. The clinical-stage biopharmaceutical firm identified Teva Pharmaceuticals as the primary stalking-horse bidder for substantially all of its assets. The disclosure triggered a severe market reaction, driving BioXcel shares down approximately 45 percent in premarket trading and reducing its market capitalization to roughly $23 million, while Teva shares experienced a minor 1 percent decline. BioXcel, which leverages artificial intelligence to develop treatments in neuroscience and immuno-oncology, faced severe operational pressure driven by heavy commercialization overhead and persistent unprofitability, with net margins exceeding negative 9,550 percent. To maintain operations and preserve access to its FDA-approved acute agitation drug IGALMI during restructuring, BioXcel secured $19 million in debtor-in-possession financing from existing lenders while awaiting court review.

By James Porter | JQJO News

Media Bias

Articles Published:: 31
Right Leaning:: 3
Left Leaning:: 0
Neutral:: 28

Explain Framing

Left: Highlights corporate leverage risks and clinical-stage biotech funding vulnerability. Center: Reports factual details regarding Chapter 11, DIP, and bidding. Right: Emphasizes free-market asset reallocations and capital market efficiency.